Daniel Shlomo Mishkin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoscopy, Gastrointestinal | 10 | 2023 | 868 | 0.770 |
Why?
|
| Endoscopes, Gastrointestinal | 7 | 2009 | 60 | 0.730 |
Why?
|
| Breath Tests | 5 | 2004 | 280 | 0.720 |
Why?
|
| Malabsorption Syndromes | 3 | 2004 | 135 | 0.600 |
Why?
|
| Gastrointestinal Agents | 3 | 2021 | 494 | 0.580 |
Why?
|
| Pregnancy Complications | 6 | 2020 | 2861 | 0.410 |
Why?
|
| Sorbitol | 2 | 2004 | 59 | 0.400 |
Why?
|
| Cathartics | 2 | 2023 | 125 | 0.400 |
Why?
|
| Sulfates | 2 | 2023 | 390 | 0.390 |
Why?
|
| Crohn Disease | 4 | 2023 | 2303 | 0.360 |
Why?
|
| Esophageal and Gastric Varices | 3 | 2008 | 207 | 0.350 |
Why?
|
| Metoclopramide | 1 | 2009 | 51 | 0.340 |
Why?
|
| Peptic Ulcer | 2 | 2020 | 223 | 0.320 |
Why?
|
| Intestine, Small | 3 | 2007 | 1241 | 0.310 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2008 | 53 | 0.300 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2007 | 504 | 0.290 |
Why?
|
| Hydrogen | 2 | 2004 | 164 | 0.280 |
Why?
|
| Pregnancy Outcome | 6 | 2020 | 2795 | 0.270 |
Why?
|
| Miniaturization | 1 | 2006 | 164 | 0.270 |
Why?
|
| Methane | 1 | 2004 | 51 | 0.240 |
Why?
|
| Catheterization, Central Venous | 1 | 2008 | 514 | 0.220 |
Why?
|
| Carbohydrate Metabolism | 1 | 2004 | 264 | 0.220 |
Why?
|
| Intestinal Perforation | 2 | 2018 | 253 | 0.220 |
Why?
|
| Colonoscopy | 4 | 2023 | 1367 | 0.210 |
Why?
|
| Colonic Diseases, Functional | 1 | 2001 | 38 | 0.200 |
Why?
|
| Magnesium Sulfate | 1 | 2021 | 68 | 0.190 |
Why?
|
| Potassium Chloride | 1 | 2021 | 237 | 0.190 |
Why?
|
| Ribavirin | 1 | 2001 | 395 | 0.170 |
Why?
|
| Polyethylene Glycols | 2 | 2023 | 1182 | 0.170 |
Why?
|
| Endosonography | 3 | 2007 | 610 | 0.170 |
Why?
|
| Cholecystitis, Acute | 1 | 2018 | 70 | 0.160 |
Why?
|
| Intestinal Obstruction | 1 | 2002 | 424 | 0.160 |
Why?
|
| Lactose Intolerance | 1 | 1997 | 27 | 0.160 |
Why?
|
| Abdominal Abscess | 1 | 2018 | 154 | 0.150 |
Why?
|
| Interferon-alpha | 1 | 2001 | 895 | 0.150 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 1997 | 122 | 0.140 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2009 | 1130 | 0.140 |
Why?
|
| Dyspepsia | 1 | 1997 | 115 | 0.140 |
Why?
|
| Laparotomy | 1 | 2018 | 473 | 0.140 |
Why?
|
| Celiac Disease | 2 | 2019 | 785 | 0.130 |
Why?
|
| Equipment Design | 10 | 2009 | 3582 | 0.130 |
Why?
|
| Fructose | 1 | 1997 | 288 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 4420 | 0.120 |
Why?
|
| Pancreatic Diseases | 2 | 2007 | 350 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 3 | 2007 | 1170 | 0.120 |
Why?
|
| Fetus | 1 | 2001 | 1880 | 0.120 |
Why?
|
| Bacterial Infections | 1 | 2001 | 1401 | 0.110 |
Why?
|
| Colitis, Ulcerative | 2 | 2021 | 1912 | 0.110 |
Why?
|
| Contrast Media | 1 | 2005 | 5300 | 0.100 |
Why?
|
| Shock, Septic | 1 | 2018 | 775 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2021 | 2250 | 0.100 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 707 | 0.100 |
Why?
|
| Ligation | 2 | 2008 | 453 | 0.090 |
Why?
|
| Glucose | 1 | 2002 | 4397 | 0.090 |
Why?
|
| Technology Assessment, Biomedical | 3 | 2007 | 306 | 0.090 |
Why?
|
| Colon | 1 | 1997 | 1772 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 9274 | 0.080 |
Why?
|
| Telemedicine | 1 | 2006 | 2872 | 0.080 |
Why?
|
| Remission Induction | 2 | 2021 | 2386 | 0.080 |
Why?
|
| Sclerosing Solutions | 1 | 2007 | 78 | 0.070 |
Why?
|
| Lithotripsy, Laser | 1 | 2007 | 46 | 0.070 |
Why?
|
| Disinfection | 1 | 2009 | 191 | 0.070 |
Why?
|
| Vena Cava, Superior | 1 | 2008 | 193 | 0.070 |
Why?
|
| Dihematoporphyrin Ether | 1 | 2006 | 31 | 0.070 |
Why?
|
| Pregnancy | 7 | 2020 | 29144 | 0.070 |
Why?
|
| Equipment Safety | 4 | 2008 | 264 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2018 | 2151 | 0.070 |
Why?
|
| Humans | 40 | 2023 | 744343 | 0.070 |
Why?
|
| Sclerotherapy | 1 | 2007 | 175 | 0.070 |
Why?
|
| Lithotripsy | 1 | 2007 | 143 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 547 | 0.070 |
Why?
|
| Digestive System Neoplasms | 1 | 2006 | 87 | 0.070 |
Why?
|
| Disposable Equipment | 1 | 2005 | 43 | 0.070 |
Why?
|
| Liver Diseases | 1 | 2014 | 1253 | 0.070 |
Why?
|
| Warfarin | 1 | 2014 | 1496 | 0.070 |
Why?
|
| Cholelithiasis | 1 | 2007 | 414 | 0.070 |
Why?
|
| Biliary Tract Diseases | 1 | 2006 | 161 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2018 | 15295 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2008 | 345 | 0.060 |
Why?
|
| Pancreatitis | 2 | 2009 | 1092 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2016 | 2119 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2007 | 566 | 0.060 |
Why?
|
| Digestive System Diseases | 1 | 2006 | 147 | 0.060 |
Why?
|
| Carbon Dioxide | 1 | 2009 | 1150 | 0.060 |
Why?
|
| Stents | 2 | 2006 | 3280 | 0.060 |
Why?
|
| Sulfur Compounds | 1 | 2023 | 31 | 0.060 |
Why?
|
| Salts | 1 | 2023 | 65 | 0.060 |
Why?
|
| Lactulose | 1 | 2002 | 33 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2007 | 694 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2014 | 3461 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2007 | 542 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2006 | 602 | 0.050 |
Why?
|
| Heart Atria | 1 | 2008 | 1357 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 1442 | 0.050 |
Why?
|
| Female | 15 | 2021 | 380194 | 0.050 |
Why?
|
| Tablets | 1 | 2021 | 145 | 0.050 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 605 | 0.050 |
Why?
|
| Fertilization | 1 | 2001 | 196 | 0.050 |
Why?
|
| Photochemotherapy | 1 | 2006 | 807 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2023 | 673 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 990 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2007 | 1486 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2014 | 4599 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1786 | 0.040 |
Why?
|
| Nausea | 1 | 2021 | 673 | 0.040 |
Why?
|
| Vomiting | 1 | 2021 | 636 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2023 | 19905 | 0.040 |
Why?
|
| Fermentation | 1 | 1997 | 144 | 0.040 |
Why?
|
| Placebos | 1 | 2021 | 1676 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 1590 | 0.040 |
Why?
|
| Gastrointestinal Transit | 1 | 1997 | 96 | 0.040 |
Why?
|
| Reference Values | 1 | 2004 | 4982 | 0.040 |
Why?
|
| Adult | 8 | 2023 | 214055 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2020 | 40561 | 0.040 |
Why?
|
| Intestinal Absorption | 1 | 1997 | 420 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2006 | 1583 | 0.030 |
Why?
|
| Reading | 1 | 2020 | 558 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 5391 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2016 | 288 | 0.030 |
Why?
|
| Current Procedural Terminology | 2 | 2006 | 92 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2021 | 1959 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2018 | 306 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 2538 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 2541 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2023 | 15540 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2020 | 25625 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 2065 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14722 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2001 | 1031 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2020 | 77449 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 10943 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2001 | 6622 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2014 | 23338 | 0.020 |
Why?
|
| Middle Aged | 5 | 2021 | 213383 | 0.020 |
Why?
|
| Bacteria | 1 | 2002 | 2114 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2014 | 676 | 0.020 |
Why?
|
| Costs and Cost Analysis | 2 | 2007 | 1681 | 0.020 |
Why?
|
| Radiography | 1 | 2002 | 7023 | 0.020 |
Why?
|
| Endoscopy | 1 | 2020 | 1785 | 0.020 |
Why?
|
| Prosthesis Design | 2 | 2006 | 2110 | 0.020 |
Why?
|
| Male | 7 | 2021 | 350118 | 0.020 |
Why?
|
| Creatinine | 1 | 2014 | 1919 | 0.020 |
Why?
|
| Mass Screening | 1 | 2004 | 5255 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 3396 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2014 | 1127 | 0.020 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 2007 | 41 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2021 | 12026 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2020 | 63114 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2004 | 21746 | 0.020 |
Why?
|
| Length of Stay | 1 | 2019 | 6309 | 0.020 |
Why?
|
| Duodenal Diseases | 1 | 2006 | 102 | 0.020 |
Why?
|
| Risk Factors | 3 | 2019 | 72290 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 166 | 0.020 |
Why?
|
| Pancreatic Ducts | 1 | 2007 | 328 | 0.020 |
Why?
|
| Stomach Diseases | 1 | 2006 | 134 | 0.020 |
Why?
|
| Laser Coagulation | 1 | 2007 | 326 | 0.020 |
Why?
|
| Esophageal Stenosis | 1 | 2006 | 195 | 0.020 |
Why?
|
| Needles | 1 | 2007 | 449 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 56430 | 0.020 |
Why?
|
| Injections | 1 | 2007 | 840 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 7181 | 0.010 |
Why?
|
| Prevalence | 1 | 2020 | 15226 | 0.010 |
Why?
|
| Aged | 3 | 2021 | 163280 | 0.010 |
Why?
|
| Research Design | 1 | 2018 | 5987 | 0.010 |
Why?
|
| Safety | 1 | 2007 | 1186 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 1641 | 0.010 |
Why?
|
| Barrett Esophagus | 1 | 2006 | 494 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13408 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2014 | 9146 | 0.010 |
Why?
|
| United States | 2 | 2020 | 69872 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 35136 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2008 | 3743 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 3036 | 0.010 |
Why?
|
| Child | 1 | 2023 | 77709 | 0.010 |
Why?
|
| Biopsy | 1 | 2007 | 6756 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 85781 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 29063 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 9959 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 11031 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 57776 | 0.010 |
Why?
|